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MaOBJECTIVES This study sought to assess the incidence and clinical impact of stent fracture (SF) after the PROMUS
Element platinum-chromium everolimus-eluting stent (PtCr-EES).
BACKGROUND SF remains an unresolved, clinically relevant issue, even in the newer-generation drug-eluting
stent era.
METHODS From March 2012 to August 2013, 816 patients with 1,094 lesions were treated only with PtCr-EES and
700 patients (85.7%) with 898 lesions undergoing follow-up angiography within 9 months after the index procedure
were analyzed. SF was deﬁned as complete or partial separation of the stent, as assessed by plain ﬂuoroscopy,
intravascular ultrasound, or optical coherence tomography during the follow-up. We assessed the rate of SF and the
cumulative incidence of clinically driven target lesion revascularization and deﬁnite stent thrombosis within 9 months
after the index procedure.
RESULTS SF was observed in 16 of 898 lesions (1.7%) and 16 of 700 patients (2.2%). Lesions with in-stent restenosis at
baseline (odds ratio [OR]: 14.2, 95% conﬁdence intervals [CI]: 5.09 to 39.7; p < 0.001) or hinge motion (OR: 4.31, 95%
CI: 1.12 to 16.5; p ¼ 0.03), and total stent length (per 10-mm increase; OR: 1.32, 95% CI: 1.12 to 1.57; p ¼ 0.001) were
predictors of SF. Cumulative incidence of clinically driven target lesion revascularization within 9-months was numeri-
cally higher in the SF group than that in the non-SF group (18.7% vs. 2.3%). Cumulative incidence of deﬁnite stent
thrombosis within 9 months after the index procedure was similar between the SF and non-SF groups (0.0% vs. 0.23%).
CONCLUSIONS SF after PtCr-EES occurs in 1.7% of lesions and appears to be associated with clinically driven target
lesion revascularization. (J Am Coll Cardiol Intv 2015;8:1180–8) © 2015 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
BES = biolimus-eluting stent
BMS = bare-metal stent(s)
CoCr-EES = cobalt chromium
everolimus-eluting stent
DES = drug-eluting stent(s)
ISR = in-stent restenosis
IVUS = intravascular
ultrasound
LSD = longitudinal stent
deformation
OCT = optical coherence
tomography
PtCr-EES = platinum-
chromium everolimus-eluting
stent
SES = sirolimus-eluting
stent(s)
SF = stent fracture
ST = stent thrombosis
TLR = target lesion
revascularization
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1181DES, we previously reported that SF after cobalt
chromium everolimus-eluting stent (CoCr-EES) im-
plantation occurs in 2.9% of lesions and is associated
with a higher rate of major adverse cardiac events,
driven by higher rates of TLR and ST (7). More
recently, we also reported SF after the Nobori
biolimus-eluting stent (BES) (Terumo, Tokyo, Japan)
implantation occurs in 4.1% of lesions, and the inci-
dence of TLR is higher in the SF lesion compared
with the non-SF lesion (8). Therefore, SF is still an un-
resolved, clinically relevant issue even in the newer-
generation DES era.
The platinum-chromium everolimus-eluting stent
(PtCr-EES) is a newer-generation DES that uses the
same drug and polymer as CoCr-EES but combines
them with a novel metal alloy and stent design
intended to improve deliverability, conformability,
radiopacity, radial strength, and fracture resistance
(9). The PLATINUM trial (A Prospective, Randomized,
Multicenter Trial to Assess an Everolimus-Eluting
Coronary Stent System [PROMUS Element] for the
Treatment of Up to Two de Novo Coronary Artery
Lesions) showed that the clinical outcome after PtCr-
EES implantation was noninferior to that after CoCr-
EES for up to 3 years (10,11). Furthermore, the
DUTCH PEERS (Durable Polymer-Based Stent Chal-
lenge of Promus Element Versus Resolute Integrity inFIGURE 1 Study Flow Chartan All Comers Population) trial demonstrated
that PtCr-EES and CoCr zotarolimus-eluting
stents were similarly efﬁcacious and safe,
and provided excellent clinical outcomes in
an all-comer population (12). However, the
incidence and clinical impact of SF after PtCr-
EES implantation remain unclear. The aim of
the present study was to assess the incidence
and clinical impact of SF after PtCr-EES
implantation.
METHODS
PATIENT POPULATION AND PROCEDURAL
PROTOCOL. From March 2012 to August 2013,
1,939 consecutive patients with 2,508 lesions
underwent successful stent implantation,
and 816 patients with 1,094 lesions were
treated only with PtCr-EES (PROMUS
Element, Boston Scientiﬁc, Natick, Massa-
chusetts) at Kokura Memorial Hospital. Of
these, 700 patients (85.7%) with 898 lesions
who underwent follow-up angiography 6 to 9
months after the initial procedure, irrespective of
clinical symptoms, or before 6 months for recurrent
symptoms, were enrolled in this study (Figure 1). All
interventions were performed using standard
TABLE 1 Baseline Pa
Age, yrs
Male
Hypertension
Diabetes
Dyslipidemia
Hemodialysis
Current smoking
Multivessel disease
No. of diseased vessels
1
2
3
Previous MI
Previous PCI
Previous CABG
Previous CI
Clinical status
Stable angina
Unstable angina
AMI
LVEF, %
Medical treatment
Aspirin
Thienopyridine
Statins
ACE-I
ARB
b-Blockers
OHA
Insulin
Values are mean  SD, n (
ACE-I ¼ angiotensin-co
receptor blocker; CABG ¼ c
fraction; MI ¼myocardial in
SF ¼ stent fracture.
Kuramitsu et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 9 , 2 0 1 5
Stent Fracture of PROMUS Element A U G U S T 1 7 , 2 0 1 5 : 1 1 8 0 – 8
1182techniques. Pre-dilation, post-dilation, and use of
intravascular ultrasound (IVUS) and optical coher-
ence tomography (OCT) were left to the operator’s
discretion. After the procedure, all patients were
advised to continue on aspirin (81 to 162 mg daily) for
life unless there were contraindications. Either ticlo-
pidine (200 mg daily) or clopidogrel (75 mg daily) was
also prescribed for at least 1 year after stent implan-
tation. All the study patients gave written informed
consent for the procedure and the follow-up protocol,
which was approved by the Institutional Review
Board of Kokura Memorial Hospital.
QUANTITATIVE ANGIOGRAPHIC ANALYSIS. Coronary
angiography was performed after the intracoronary
administration of 0.2 mg of nitroglycerin. Quantitative
coronary angiographic analysis was performedtient Characteristics
Overall
(N ¼ 700)
SF
(n ¼ 16)
Non-SF
(n ¼ 684) p Value
69.7  9.7 69.1  6.7 69.6  9.7 0.84
511 (73.0) 11 (68.7) 500 (73.1) 0.77
562 (80.0) 13 (81.2) 549 (80.2) >0.99
320 (45.5) 7 (43.7) 313 (45.7) >0.99
580 (82.6) 13 (81.2) 567 (82.8) 0.74
71 (10.1) 4 (25.0) 67 (9.8) 0.07
120 (17.1) 4 (25.0) 116 (16.9) 0.49
202 (28.9) 5 (31.2) 197 (28.8) 0.78
0.64
499 (71.1) 11 (68.7) 488 (71.3)
175 (25.0) 5 (31.2) 170 (24.9)
26 (3.7) 0 (0.0) 26 (3.8)
140 (19.9) 4 (25.0) 136 (19.8) 0.53
314 (44.7) 8 (50.0) 306 (44.7) 0.80
36 (5.1) 1 (6.2) 35 (5.1) 0.57
53 (7.6) 1 (6.2) 52 (7.6) >0.99
0.58
611 (87.3) 14 (87.5) 597 (87.3)
20 (2.8) 0 (0.0) 20 (2.9)
69 (9.8) 2 (12.5) 67 (9.8)
59.9 (50.6–65.9) 53.0 (41.3–62.7) 60.0 (51.0–66.1) 0.014
700 (100.0) 16 (100.0) 684 (100.0) —
699 (99.8) 16 (100.0) 683 (99.8) >0.99
541 (77.0) 11 (68.7) 530 (77.4) 0.37
132 (18.8) 6 (37.5) 126 (18.4) 0.09
311 (44.3) 7 (43.7) 304 (44.4) >0.99
293 (41.9) 9 (56.2) 284 (41.5) 0.30
240 (34.1) 4 (25.0) 236 (34.5) 0.59
63 (8.9) 1 (6.2) 62 (9.0) >0.99
%), or median (interquartile range [IQR]).
nverting enzyme inhibitor; AMI ¼ acute myocardial infarction; ARB ¼ angiotensin
oronary artery bypass graft; CI ¼ cerebral infarction; LVEF ¼ left ventricular ejection
farction; OHA ¼ oral hypoglycemia agent; PCI ¼ percutaneous coronary intervention;before and after stenting and during follow-up angi-
ography, using a guiding catheter to calibrate the
magniﬁcation and a validated automated edge-
detection algorithm (CASS 5.7, Pie Medical Imaging,
Eindhoven, the Netherlands). The analyses were per-
formed independently by 2 experienced observers of
the Angiographic Core Laboratory, Kokura Memorial
Hospital, blinded to the clinical information. The
target lesion for measurement of the minimal luminal
diameter included 5-mm margins proximal and
distal to the stent as well as the stent itself. ISR was
deﬁned as a percent diameter stenosis of >50% within
the stent at the time of follow-up. In-segment reste-
nosis was deﬁned as a percent diameter stenosis of
>50% either within the stented segment or within the
5 mm proximal or distal to the stent segment. The
angiographic ISR patterns were classiﬁed as focal or
diffuse according to Mehran’s classiﬁcation (13). A
hinge-motion lesion was deﬁned as having $16 dif-
ference in angle between diastole and systole before
the procedure (14).
STUDY ENDPOINT AND DEFINITIONS. The study
primary endpoint was the incidence of SF within
9 months after PtCr-EES implantation. The secondary
endpoint was the cumulative incidence of clinically
driven TLR and deﬁnite ST within 9 months after the
index procedure. A clinically driven TLR was deﬁned
as a >70% diameter stenosis on follow-up angiog-
raphy in the presence of signs or symptoms of
myocardial ischemia. The timing and diagnostic cer-
tainty of ST were assessed according to the Academic
Research Consortium deﬁnition (15).
SF was deﬁned as complete or partial separation of
stent segments observed by plain ﬂuoroscopy
without contrast injection, IVUS, or OCT at follow-up
angiography (8). The angiographic diagnosis of SF
required an independent review and the agreement
of 2 independent cardiologists (T.H. and S.E.).
Angiographic SF was classiﬁed as follows: type 1
(partial separation), type 2 (complete separation
without displacement), or type 3a and 3b (complete
separation with displacement) (9). Diagnosis of SF by
IVUS or OCT required careful review of the IVUS or
OCT images and the agreement of 2 independent
cardiologists (T.D. and M.H.). SF observed by IVUS
and OCT was classiﬁed as complete (complete sepa-
ration of the stent into $2 pieces separated by
image slices with no visible struts) or partial (the
absence of struts over one-half or more of the stent
circumference).
STATISTICAL ANALYSIS. Data are presented as
values and percentages, mean  SD, or median
(interquartile range [IQR]). Categorical variables were
TABLE 2 Baseline Lesion Characteristics
Overall
(N ¼ 898)
SF
(n ¼ 16)
Non-SF
(n ¼ 882) p Value
Location of target lesion 0.025
RCA 326 (36.1) 13 (81.2) 313 (35.2)
LAD 370 (40.9) 2 (12.5) 368 (41.4)
LCX 195 (21.5) 1 (6.3) 194 (21.8)
LMT 7 (0.7) 0 (0.0) 7 (0.7)
SVG 3 (0.3) 0 (0.0) 3 (0.3)
LITA 1 (0.1) 0 (0.0) 1 (0.1)
GEA 1 (0.1) 0 (0.0) 1 (0.1)
Lesion type 0.07
A 44 (5.3) 0 (0.0) 44 (5.4)
B1 247 (29.9) 4 (28.5) 243 (30.0)
B2 187 (22.6) 0 (0.0) 187 (23.0)
C 346 (41.9) 10 (71.4) 336 (41.4)
In-stent restenosis 82 (9.0) 7 (43.7) 74 (8.3) <0.001
Calciﬁcation 77 (8.5) 2 (12.5) 75 (8.5) 0.64
Tortuosity 427 (47.5) 12 (75.0) 415 (47.0) 0.04
Hinge motion 274 (30.5) 11 (68.7) 263 (29.8) 0.001
Bifurcation 236 (26.2) 2 (12.5) 234 (26.5) 0.26
Ostial location 17 (1.8) 1 (6.2) 16 (1.8) 0.26
Chronic total occlusion 72 (8.0) 2 (12.5) 70 (7.9) 0.37
Stent diameter, mm 2.8  0.4 2.9  0.4 2.8  0.4 0.37
Total stent length, mm 24.0 (20.0–38.0) 48.0 (21.0–62.0) 24.0 (20.0–38.0) 0.018
No. of stents per lesion 0.002
1 683 (76.1) 7 (43.8) 676 (76.6)
2 172 (19.1) 6 (37.5) 166 (18.8)
$3 43 (4.8) 3 (18.7) 40 (4.5)
Maximal pressure, atm 15.1  4.2 16.3  3.0 15.1  4.2 0.10
Post dilation 443 (49.3) 10 (62.5) 433 (49.0) 0.32
Stent overlap 204 (22.7) 9 (56.2) 195 (22.1) 0.003
Use of IVUS or OCT 881 (98.1) 15 (93.7) 866 (98.1) 0.26
QCA results
Lesion length, mm 26.0  12.9 37.0  17.2 25.8  12.8 0.004
RVD at baseline, mm 2.58  0.40 2.61  0.52 2.58  0.39 0.78
Pre-MLD, mm 0.63  0.37 0.60  0.48 0.63  0.37 0.94
Pre-%DS, % 71.8  15.0 75.5  19.5 71.7  14.9 0.63
Post-MLD, mm 2.17  0.36 2.12  0.47 2.17  0.36 0.61
Post-%DS, % 15.8  6.7 18.8  7.2 15.8  6.6 0.07
In-stent restenosis
Focal 82 (9.1) 7 (43.7) 75 (8.5) <0.001
Diffuse 14 (1.6) 2 (12.5) 12 (1.3) <0.001
Overall 96 (10.7) 9 (56.2) 87 (9.8) <0.001
In-segment restenosis 104 (11.6) 9 (56.2) 95 (10.8) <0.001
Values are n (%), mean  SD, or median (IQR).
DS ¼ diameter stenosis; GEA ¼ gastroepiploic artery; IVUS ¼ intravascular ultrasound; LAD ¼ left anterior
coronary artery; LCX ¼ left circumﬂex coronary artery; LITA ¼ left internal thoracic artery; LMT ¼ left main trunk;
MLD ¼ minimal lumen diameter; OCT ¼ optical coherence tomography; QCA ¼ quantitative coronary angiog-
raphy; RCA ¼ right coronary artery; RVD ¼ reference vessel diameter; SVG ¼ saphenous vein graft; other
abbreviations as in Table 1.
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1183compared between groups with the chi-square test
or Fisher exact test, as appropriate. Continuous var-
iables were compared between groups using the
Student unpaired t test or the Mann-Whitney U test,
on the basis of the distribution. For the lesion-based
analysis of the risk factors for SF, we used unad-
justed and multivariable-adjusted logistic regression
models with random intercepts that accounted for the
clustered nature of lesion characteristics within pa-
tients. The following 6 variables with p < 0.05 in the
univariate analysis were tested for their multivariable
predictive value: ISR at baseline, hinge motion, right
coronary artery, total stent length (per 10-mm in-
crease), tortuosity, and stent overlap. The ﬁnal model
was constructed using the 4 variables: ISR at baseline,
hinge motion, right coronary artery, and total stent
length (per 10-mm increase) selected by forward
stepwise method in standard logistic regression pro-
gram, with both entry and exit criteria set at the
p ¼ 0.05 level. Cumulative incidence of clinically
driven TLR, and ST within 9 months after the index
procedure, between lesions with SF and those
without SF was estimated by the Kaplan-Meier
method. Because of the small number of events in
the SF and non-SF groups, statistical comparisons
were not conducted for the cumulative event rates.
All statistical analyses were performed by a physician
(S.K.) and a statistician (T.S.) using JMP version 10.0.2
and SAS version 9.4 (SAS Institute, Cary, North Car-
olina). Random-intercept logistic models were ﬁtted
through the pseudo-likelihood method on the basis of
outcome linearization in the SAS GLIMMIX procedure
and other analyses were carried out in JMP software.
A 2-sided p value of <0.05 was considered statisti-
cally signiﬁcant.
RESULTS
Of 816 patients, 700 patients (85.7%) with 898
lesions who underwent follow-up angiography 6 to
9 months after the initial procedure, irrespective of
clinical symptoms, or before 6 months for recurrent
symptoms, were enrolled in this study (Figure 1).
Coronary angiography was performed 190 days
(IQR: 183 to 234 days) after the index procedure.
Baseline characteristics of the 700 patients with
follow-up angiography included in this study were
not signiﬁcantly different from those of the 116
patients without angiography except for age, male
sex, dyslipidemia, left ventricular ejection fraction,
and statin use (Online Table 1). At follow-up, SF
after PtCr-EES implantation was recognized in 16
of 898 lesions (1.7%) and in 16 of 700 patients(2.2%). In 15 of the 16 lesions (93.7%), SF was
found at a single point, whereas SF occurred in 2 or
more points per lesion in 1 lesion (6.3%). As a
result, a total of 18 fractures in 16 lesions was
observed.
FIGURE 2 Angiogr
(A) Classiﬁcation of
cation and target les
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1184CLINICAL CHARACTERISTICS. The baseline clinical
characteristics of the SF and non-SF groups are shown
in Table 1. There were no signiﬁcant differences be-
tween the 2 groups except for left ventricular ejection
fraction.
ANGIOGRAPHIC AND PROCEDURAL CHARACTERISTICS
AND RESULTS. The angiographic and procedural
characteristics and results of both groups are shown
in Table 2. Compared with the non-SF group, the
prevalence of the right coronary artery location, ISR
at baseline, tortuosity, and hinge motion were
signiﬁcantly higher in the SF group. Index stent types
that caused ISR at baseline included as follows:
33 BMS, 27 BES, 12 sirolimus-eluting stents (SES),
6 CoCr-EES, and 4 paclitaxel-eluting stents. Of these,
17 ISR (20.7%) were associated with SF (14 BES,
1 SES, 1 SES, and 1 CoCr-EES). Although stent size was
similar between the 2 groups, signiﬁcant differences
were found in total stent length, number of stents per
lesion, and the rate of lesions treated with $2 stents.aphic Classiﬁcation of SF and Clinical Outcome
angiographic SF. (B) Relationships between angiographic SF classiﬁ-
ion revascularization (TLR). CD ¼ clinically driven; SF ¼ stent fracture.Pre-procedure lesion length was signiﬁcantly longer
in the SF group than in the non-SF group (p ¼ 0.004).
Post-procedure percent diameter stenosis tended to
be higher in the SF group than in the non-SF group
(p ¼ 0.07). In SF lesions with hinge motion, the point
of fracture was well accorded with the point of hinge
motion. At follow-up, ISR and in-segment restenosis
occurred more frequently in the SF group than in the
non-SF group (p < 0.001). In the SF group, 56.2% of SF
sites were associated with ISR at follow-up. The
angiographic patterns of ISR at follow-up were mostly
focal (85.4%) in both groups. Among 7 ISR lesions at
follow-up in the SF group, 3 (42.9%) were ISR at
baseline related to SF after BES implantation. In the
remaining 4 ISR lesions (57.1%), all SFs occurred in
the portion of previously implanted stent edge,
leading to the point of hinge motion. No coronary
aneurysm formation was observed in the SF group.
CLASSIFICATION AND INDEPENDENT PREDICTORS
OF STENT FRACTURE. All SFs were angiographically
visible SFs, in which 8 (44.4%) were type 2, 5 (27.8%)
were type 3a, and 5 (27.8%) were type 3b (Figure 2A).
Figure 2B show the classiﬁcation of angiographic SF
and the relationship between angiographic SF classi-
ﬁcation and TLR. Figure 3 and Online Figure 1
show representative cases with type 2, 3a, and 3b SFs.
In the present study, 5 (27.8%) SFs were detected by
using IVUS or OCT and performing a careful review of
the angiogram. All SFs detected by using IVUS or OCT
were complete fractures. The SFs were located in the
mid-portion (50%), overlap portion (22.2%), proximal
portion (16.7%), and distal portion (11.1%).
The predictors of SF after PtCr-EES implantation on
multivariable logistic analysis are shown in Table 3. ISR at
baseline (odds ratio [OR]: 14.2, 95% conﬁdence interval
[CI]: 5.09 to 39.7; p <0.001), hinge motion (OR: 4.31, 95%
CI: 1.12 to 16.5; p¼0.03), and total stent length (per 10-mm
increase; OR: 1.32, 95% CI: 1.12 to 1.57; p ¼ 0.001), were
identiﬁed as predictors of SF after PtCr-EES implantation.
CLINICAL OUTCOMES. Clinically driven TLR was
performed in 3 lesions with SF and 21 lesions without
SF. Cumulative incidence of clinically driven TLR was
numerically higher in the SF group than in the non-SF
group (18.7% vs. 2.3%) (Figure 4). Although deﬁnite
ST occurred in 2 lesions without SF (0.23%) at 5 and
32 days after PtCr-EES implantation, it did not occur
in lesions with SF (Figure 5).DISCUSSION
The main ﬁndings of the present study are: 1) the
incidence of SF after PtCr-EES implantation was 1.7%
FIGURE 3 Representative Case of SF
(A) Coronary angiography shows a lesion with chronic total occlusion in the middle right coronary artery. (B) Final results after implantation of
4 platinum-chromium everolimus-eluting stents with overlap (3.5  20 mm [white line], 3.5  38 mm [red line], 2.5  28 mm [yellow line],
and 2.25  28 mm [blue line]). (C) At 6 months after implantation, angiography shows a total of 3 stent fractures (SFs) with 50% stenosis
(white arrow), 99% stenosis (red arrow), and total occlusion (yellow arrow) at the distal portion of the implanted stent. (D) Coronary
computed tomography angiography shows type 2 SFs (white and yellow arrows) and type 3b SF (red arrow).
TABLE 3 Multivariable Logistic Regression Analysis of SF
OR* 95% CI p Value
In-stent restenosis at baseline 14.20 5.09–39.7 <0.001
Total stent length (per 10-mm increase) 1.32 1.12–1.57 0.001
Hinge motion 4.31 1.12–16.5 0.03
Right coronary artery 3.92 0.84–18.2 0.08
For all variables, p < 0.05 by unadjusted analysis with stent fracture (SF).
*Random intercepts in the model accounted for within-patient clustering of lesion
characteristics.
CI ¼ conﬁdence interval; OR ¼ odds ratio.
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1185of lesions; 2) SF appeared to be associated with higher
rates of TLR; and 3) lesions with ISR at baseline, hinge
motion, and total stent length were identiﬁed as
predictors of SF.
The incidence of SF in the clinical setting has been
reported to be 0.84% to 8.4% in ﬁrst-generation DES
(5,6). Of the newer-generation DES, we previously
reported that SF after CoCr-EES and BES implantation
was observed in 2.9% and 4.1% of lesions, respec-
tively, and was associated with a higher rate of major
cardiac events, mainly driven by higher TLR or ST
(7,8). The PROMUS Element is a newer-generation
DES with a novel metal alloy and stent design inten-
ded to improve deliverability and conformability,
increase radial strength and radiopacity, and reduce
recoil compared with previous DES. Bench testing
indicates the PtCr-EES may be less likely than other
DES to develop strut fracture over time (16). However,
there are currently no data regarding the incidence
and clinical impact of SF after PtCr-EES implantation.
In the present study, despite a high prevalence of
lesions with hinge motion or tortuosity, the incidence
of SF after PtCr-EES implantation was 1.7% of lesions,which was lower than that after CoCr-EES and BES
implantation (7,8). Therefore, PtCr-EES may be more
resistant to fractures as compared with CoCr-EES
and BES.
An optimal stent design incorporates a balance of
desirable characteristics; however, an improvement
in one feature may adversely affect other attributes of
the stent platform. PtCr-EES is reportedly prone to
longitudinal stent deformation (LSD) by adjunctive
devices, instead of higher ﬂexibility (17). Indeed, LSD
occurred in 0.56% of lesions in the current study. The
FIGURE 4 Cumulative Incidence Curves of Clinically Driven TLR Within 9 Months
Blue line indicates SF patients; red line, non-SF patients. PtCrEES ¼ platinum-chromium
everolimus-eluting stent; other abbreviations as in Figure 2.
FIGURE 5 Cumulative Incidence Curves of Deﬁnite ST Within 9 Months
Blue line indicates SF patients; red line, non-SF patients. ST ¼ stent thrombosis; other
abbreviations as in Figures 2 and 4.
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1186contributors of SF are not only ﬂexibility, but also
longitudinal strength because repetitive cardiac
contraction exposes the stent to compression, tor-
sion, elongation, bending, and shear stress. These
ﬁndings were supported by the presence of type 3b SF
(8). Therefore, there is a little concern that type 3b SF
might be likely to occur in PtCr-EES. In the present
study, type 3b SF occurred in 27.8% of all SF lesions
and was not more frequently observed in SF after
PtCr-EES implantation. Moreover, it is intriguing that
hinge motion was not the largest contributor to SF
after PtCr-EES implantation, and tortuosity was not
found to be a predictor, which were completely
different results from CoCr-EES and BES (7,8). These
ﬁndings suggest that ﬂexibility plays the pivotal role
in the incidence of SF rather than longitudinal
strength, and some SFs are unavoidable even in PtCr-
EES because the stent is made of metal. Nevertheless,
if a de novo lesion was treated with a single stent,
including the 38-mm PtCr-EES, the incidence of SF
after PtCr-EES implantation was very rare (0.48%) in
the present study. Therefore, PtCr-EES may reduce
the incidence of SF to the utmost limit of a metallic
DES.
SF has been associated with a higher potential risk
of ISR, TLR, and ST in the ﬁrst-generation DES (4). We
previously reported that SF after CoCr-EES and BES
implantation was associated with major adverse car-
diac events within 9 months after the index proce-
dure, primarily because of clinically driven TLR or ST
(8,9). Similarly, the present study showed a higher
incidence of clinically driven TLR after PtCr-EES im-
plantation in the SF group compared with the non-SF
group. Therefore, SF remains an issue even in PtCr-
EES. On the other hand, ST did not occur in the SF
group in the present study. Although the current study
has a potential for underestimation because of a rela-
tively small study population and the very low inci-
dence of SF, the lack of ST might be due to differences
in stent platform between PtCr-EES and other DES.
To date, there is no consensus regarding the
optimal treatment for SF lesions. In the present
study, a total of 16 SF lesions after implantation with
other DES were treated with subsequent PtCr-EES
implantation. Recurrent SF occurred in 3 (18.7%) of
those SF lesions and was associated with a high rate
of TLR (66.7%). Although it remains unclear which
DES is suitable for the treatment of SF lesions, it
should be recognized that some SF become refractory
to PCI once it occurs. Recently, paclitaxel-eluting
balloon angioplasty was shown to be superior to un-
coated balloon angioplasty for the treatment of ISR
after BMS and DES (18–20). Although the mechanism
of ISR in SF sites has not been fully evaluated, an
PERSPECTIVES
WHAT IS KNOWN? SF is still an unresolved, clinically relevant
issue even in the newer-generation DES era. PtCr-EES is a newer-
generation DES that uses the same drug and polymer as CoCr-
EES but combines them with a novel metal alloy and stent design
intended to improve fracture resistance. However, the incidence
and clinical impact of SF after PtCr-EES implantation remain
unclear.
WHAT IS NEW? A total of 700 patients with 898 lesions un-
dergoing PtCr-EES implantation were analyzed. SF was observed
in 16 of 898 lesions (1.7%). Lesions with ISR at baseline or hinge
motion, and total stent length were predictors of SF. The cu-
mulative incidence of clinically driven TLR within 9 months after
the index procedure was numerically higher in the SF group than
that in the non-SF group (18.7% vs. 2.3%), whereas deﬁnite ST
did not occur in the SF group.
WHAT IS NEXT? PtCr-EES may reduce the incidence of SF to
the utmost limit of a metallic DES.
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1187OCT study showed that neointimal hyperplasia is
increased at fracture sites after SES implantation (21).
Therefore, paclitaxel-eluting balloon angioplasty
might be an alternative treatment for SF lesions. Most
importantly, however, clinicians should select DES
with a lower tendency to fracture in lesions at high
risk for SF. Taking the results of the present and
previous studies into consideration, PtCr-EES might
become the ﬁrst-choice DES for such lesions.
STUDY LIMITATIONS. First, this study was a single-
center study, and follow-up angiography was not
performed in all patients. Therefore, selection bias
may exist in the present study and may have biased
the conclusion. Second, IVUS and OCT were not per-
formed in all patients undergoing follow-up angi-
ography. In addition, the detection of partial SF on
angiogram was limited because of its spatial resolu-
tion, regardless of high visibility on plain ﬂuoroscopy
of PtCr-EES. Therefore, the present study may have
underestimated the incidence of SF. Third, despite
the fact that we selected modeling variables using the
tight criteria of p < 0.05, instead of the usually
adopted p < 0.10 or 0.20, the ﬁndings from multivar-
iable modeling with 4 variables should be interpreted
with caution because of the small number of patients
with fracture (n ¼ 16). Our sensitivity analysis of
random-intercept logistic regression using other
combinations among ﬁnally selected 4 variables
showed that the estimated OR varied in some magni-
tude, but their direction and p values were stable
throughout almost all the models (Online Table 2). We
also ﬁtted the model (without random effects) via
Firth’s penalized likelihood and an exact method,
which provided essentially the same OR estimates and
p values. Finally, the association between ISR and SF
was marked in the present study. It might be due to
ascertainment bias, that is, ISR lesions were more
carefully scrutinized for evidence of SF.CONCLUSIONS
SF after PtCr-EES implantation occurs in 1.7% of le-
sions and appears to be associated with clinically
driven TLR. Lesions with ISR or hinge motion and the
total stent length are predictors of SF.
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